We aimed to quantify the DNA of maternal chimeric (MC) cells in the peripheral blood of the BA patients and investigated the impact on the outcome.

Patients with progressive jaundice because of no bile flow, which necessitated liver transplantation, or who showed inadequate bile flow with or without episodes of cholangitis and progressive hepatic fibrosis and portal hypertension were classified into the poor group. Those with adequate bile flow with completely normal liver function tests beyond 2 years were classified into the good group. The qPCR were separately carried out in buffy coat samples and plasma samples, targeting the non-inherited maternal HLA alleles in the DNA samples.

MC-DNA was present in the buffy coat (10–328 gEq per 10⁶ host cells) in seven patients. There was no MC-DNA in the remaining five patients. MC-DNA (214–15,331 gEq per 10⁶ host cells) was observed in the plasma of five patients. The quantity of MC-DNA in the buffy coat showed a significant difference between the two prognostic groups (p = 0.018), whereas there was no significant difference in the quantity of MC-DNA in plasma (p = 0.205). MC-DNA in the buffy coat was significantly associated with the outcome (p = 0.028), whereas MC-DNA in the plasma did not influence the outcome (p = 0.56).

Poor outcomes in BA were correlated with circulating maternal chimeric lymphocytes.

我们旨在量化 BA 患者外周血中母体嵌合 (MC) 细胞的 DNA，并研究其对结果的影响。

因无胆汁流动而出现进行性黄疸、需要进行肝移植或胆汁流量不足伴或不伴胆管炎、进行性肝纤维化和门静脉高压症的患者被分类为较差组。2年以上胆汁流量充足、肝功能完全正常者为良组。qPCR 分别在血沉棕黄层样品和血浆样品中进行，针对 DNA 样品中的非遗传​​母体 HLA 等位基因。

^{7 名患者的血沉棕黄层中存在 MC-DNA（每 10 6 个}宿主细胞10-328 gEq ）。其余五名患者没有MC-DNA。在五名患者的血浆中观察到MC-DNA（每 10 ^{6 个}宿主细胞214–15,331 gEq ）。血沉棕黄层中 MC-DNA 的数量在两个预后组之间显示出显着差异（p= 0.018），而血浆中 MC-DNA 的数量没有显着差异（p= 0.205)。血沉棕黄层中的 MC-DNA 与结果显着相关（p= 0.028），而血浆中的 MC-DNA 不影响结果（p= 0.56)。

BA 的不良结果与循环母体嵌合淋巴细胞相关。